PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR S1P5-MEDIATED DISEASES

• Main Authors: KOMIYA TAKAKI, WATANABE TOSHIHIDE, TSUBURAYA NAOMI, KUSUMI KENSUKE, IMAIDE SATOMI, ENDO TOSHIMITSU
• Format: Patent
• Language: English; Japanese
• Published: 04.03.2021
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

To provide pharmaceutical compositions containing, as an active ingredient, a compound having an improved balance of S1P5 receptor agonist activity to S1P1 receptor, and to provide medicines that use them to prevent and/or treat S1P5-mediated diseases (for examples, neurodegenerative diseases, multiple system atrophy, Parkinson's disease).SOLUTION: Provided is a pharmaceutical composition containing a compound represented by general formula (V) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, specifically, for example a compound such as 1-[((3R)-6-butoxy-3-methyl-3,4-dihydronaphthalene-2-yl) methyl] azetidine-3-carboxylic acid.SELECTED DRAWING: None 【課題】Ｓ１Ｐ１受容体に対するＳ１Ｐ５受容体作動活性のバランスを改善させた化合物を有効成分として含有する医薬組成物、ならびにそれらをＳ１Ｐ５介在性疾患（例えば、神経変性疾患、多系統萎縮症、パーキンソン病）の予防および／または治療に用いる医薬の提供。【解決手段】一般式（Ｖ）で示される化合物またはその薬学的に許容される塩と薬学的に許容される担体とを含有する医薬組成物であって、具体的には、例えば１−［（（３Ｒ）−６−ブトキシ−３−メチル−３，４−ジヒドロナフタレン−２−イル）メチル］アゼチジン−３−カルボン酸等の化合物。【選択図】なし